Equities researchers at StockNews.com assumed coverage on shares of Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) in a report issued on Tuesday. The brokerage set a “hold” rating on the medical research company’s stock.
Accelerate Diagnostics Stock Up 1.6 %
Shares of NASDAQ AXDX opened at $1.88 on Tuesday. The company has a market capitalization of $41.46 million, a PE ratio of -0.46 and a beta of 0.61. The stock’s 50 day moving average price is $1.76 and its 200-day moving average price is $1.38. Accelerate Diagnostics has a twelve month low of $0.73 and a twelve month high of $6.25.
Accelerate Diagnostics (NASDAQ:AXDX – Get Free Report) last announced its quarterly earnings data on Thursday, August 8th. The medical research company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.55) by $0.05. The business had revenue of $2.99 million during the quarter, compared to the consensus estimate of $3.00 million. As a group, research analysts expect that Accelerate Diagnostics will post -2.14 EPS for the current fiscal year.
Hedge Funds Weigh In On Accelerate Diagnostics
Accelerate Diagnostics Company Profile
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Read More
- Five stocks we like better than Accelerate Diagnostics
- 3 Home Improvement Stocks that Can Upgrade Your Portfolio
- Boeing: Why Analysts Think Now’s The Time To Be Brave
- High Dividend REITs: Are They an Ideal Way to Diversify?
- Advanced Micro Devices is Building Momentum with AI: Buy the Dip
- How to Evaluate a Stock Before BuyingÂ
- Can Evolv Stock Recover From Its Massive Self-Inflicted Drop?
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.